Completed PHASE3 INTERVENTIONAL 2-arm NCT04115293

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE)

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Sponsor: Ra Pharmaceuticals, Inc.

Conditions Myasthenia Gravis, Generalized

Interventions Placebo zilucoplan (RA101495)

Updated 27 times since 2019 Last updated: Jul 4, 2025 Started: Sep 17, 2019 Primary completion: Dec 30, 2021 Completion: Dec 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Myasthenia Gravis, Generalized, this trial is completed. The trial is conducted by Ra Pharmaceuticals, Inc. and has accumulated 27 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

27 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Aug 2025 — Sep 2025 [monthly]

Completed PHASE3
Nov 2024 — Aug 2025 [monthly]

Completed PHASE3
Sep 2024 — Nov 2024 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3

▶ Show 22 earlier versions

Jun 2024 — Jul 2024 [monthly]

Completed PHASE3
Jun 2023 — Jun 2024 [monthly]

Completed PHASE3
Feb 2023 — Jun 2023 [monthly]

Completed PHASE3
Sep 2022 — Feb 2023 [monthly]

Completed PHASE3
Jun 2022 — Sep 2022 [monthly]

Completed PHASE3
May 2022 — Jun 2022 [monthly]

Completed PHASE3
Apr 2022 — May 2022 [monthly]

Completed PHASE3
Feb 2022 — Apr 2022 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jan 2022 — Feb 2022 [monthly]

Active Not Recruiting PHASE3
Dec 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE3
Nov 2021 — Dec 2021 [monthly]

Active Not Recruiting PHASE3
Oct 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE3
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE3
May 2021 — Jun 2021 [monthly]

Recruiting PHASE3
Apr 2021 — May 2021 [monthly]

Recruiting PHASE3
Mar 2021 — Apr 2021 [monthly]

Recruiting PHASE3
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE3
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Nov 2020 — Dec 2020 [monthly]

Recruiting PHASE3
Nov 2019 — Nov 2020 [monthly]

Recruiting PHASE3

First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ra Pharmaceuticals, Inc.

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Augusta, United States , Austin, United States , Barcelona, Spain , Bergen, Norway , Bilbao, Spain , Chapel Hill, United States , Charleston, United States , Charlottesville, United States , Chiba, Japan and 58 more locations